MX2024001824A - Compuestos heterociclicos y metodos de uso. - Google Patents

Compuestos heterociclicos y metodos de uso.

Info

Publication number
MX2024001824A
MX2024001824A MX2024001824A MX2024001824A MX2024001824A MX 2024001824 A MX2024001824 A MX 2024001824A MX 2024001824 A MX2024001824 A MX 2024001824A MX 2024001824 A MX2024001824 A MX 2024001824A MX 2024001824 A MX2024001824 A MX 2024001824A
Authority
MX
Mexico
Prior art keywords
compounds
methods
heterocyclic compounds
compositions
formula
Prior art date
Application number
MX2024001824A
Other languages
English (en)
Spanish (es)
Inventor
Brian Alan Lanman
Ning Chen
Wei Zhao
John Stellwagen
Ryan Paul Wurz
Liping Pettus
Francesco Manoni
Rene Rahimoff
Michael M Yamano
Primali Navaratne
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2024001824A publication Critical patent/MX2024001824A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024001824A 2021-08-10 2022-08-10 Compuestos heterociclicos y metodos de uso. MX2024001824A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163231543P 2021-08-10 2021-08-10
US202163289578P 2021-12-14 2021-12-14
US202263299667P 2022-01-14 2022-01-14
PCT/US2022/039969 WO2023018810A1 (en) 2021-08-10 2022-08-10 Heterocyclic compounds and methods of use

Publications (1)

Publication Number Publication Date
MX2024001824A true MX2024001824A (es) 2024-02-28

Family

ID=85200999

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001824A MX2024001824A (es) 2021-08-10 2022-08-10 Compuestos heterociclicos y metodos de uso.

Country Status (8)

Country Link
US (1) US20240417412A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384177A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024532733A (cg-RX-API-DMAC7.html)
AU (1) AU2022325858A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228338A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001824A (cg-RX-API-DMAC7.html)
TW (1) TW202317566A (cg-RX-API-DMAC7.html)
WO (1) WO2023018810A1 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
AU2022220678A1 (en) * 2021-02-09 2023-09-21 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
US20240109918A1 (en) * 2022-05-04 2024-04-04 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
US20240116951A1 (en) * 2022-05-04 2024-04-11 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
AU2023265688A1 (en) 2022-05-06 2024-10-17 PAQ Therapeutics Inc. Kras g12d proteolysis targeting chimeras
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
KR20250109197A (ko) 2022-11-21 2025-07-16 트리라인 바이오사이언시스, 인크. 스피로환식 디하이드로피라노피리미딘 KRas 억제제
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
KR20260054710A (ko) 2023-08-17 2026-04-22 트리라인 바이오사이언시스, 인크. 스피로시클릭 디히드로피라노피리미딘 KRas 저해제
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
KR20260087586A (ko) 2023-10-03 2026-06-11 피에이큐 테라퓨틱스 인코포레이티드 Kras 단백질분해 표적화 키메라
CN122374018A (zh) 2023-10-06 2026-07-10 美国安进公司 用于癌症治疗的组合疗法
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128172A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
UA127968C2 (uk) * 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) * 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
AU2020369569B2 (en) * 2019-10-24 2026-06-18 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
EP4262807A4 (en) * 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
EP4332105A4 (en) * 2021-04-30 2025-05-28 Genfleet Therapeutics (Shanghai) Inc. PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
BR112023024906A2 (pt) * 2021-05-28 2024-02-15 Redx Pharma Plc Compostos
AU2022304939A1 (en) * 2021-06-30 2024-02-08 Shanghai Allist Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, and preparation method therefor, intermediate thereof, and application thereof

Also Published As

Publication number Publication date
US20240417412A1 (en) 2024-12-19
EP4384177A4 (en) 2025-09-10
JP2024532733A (ja) 2024-09-10
AU2022325858A1 (en) 2024-02-15
TW202317566A (zh) 2023-05-01
EP4384177A1 (en) 2024-06-19
WO2023018810A1 (en) 2023-02-16
CA3228338A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
JOP20240216A1 (ar) مثبطات kras g12c
MX2025001680A (es) Compuestos heterociclicos, composiciones de los mismos y metodos de tratamiento con ellos
JOP20230318A1 (ar) مشتقات تترا هيدرو – إيميدازوبيريدين كمعدِّلات مناعية pd-l1
MX2025011447A (es) Inhibidores de kras
PH12020551464A1 (en) Cd73 inhibitors
GEAP202215535A (en) Compounds
MX2021009276A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2.
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
GEAP202215475A (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
MX390625B (es) Inhibidores selectivos de jak1.
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
EA201400111A1 (ru) Ингибиторы mek и способы их применения
NO20083207L (no) Inhibitorer av IAP
EA201991884A2 (ru) Ингибиторы g12c kras
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
CL2023001367A1 (es) Inhibidores de btk
MX2022009059A (es) Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a.
WO2021030379A9 (en) Bicyclic heteroaryl compounds useful as irak4 inhibitors
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.